Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nam, J.-S.
Right arrow Articles by Hirohashi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nam, J.-S.
Right arrow Articles by Hirohashi, S.
Clinical Cancer Research Vol. 8, 2430-2436, July 2002
© 2002 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

Src Family Kinase Inhibitor PP2 Restores the E-Cadherin/Catenin Cell Adhesion System in Human Cancer Cells and Reduces Cancer Metastasis1

Jeong-Seok Nam, Yoshinori Ino, Michiie Sakamoto and Setsuo Hirohashi2

Pathology Division, National Cancer Center Research Institute, Tokyo 104-0045, Japan

The E-cadherin/catenin cell adhesion system is often down-regulatedin epithelial tumors. This is thought to play an important role in cancer invasion and metastasis. Restoring this system may enable suppression of the metastatic spread of cancer. This study examined the effect of Src family kinase inhibitor PP2 on E-cadherin-mediated cell-cell adhesion and metastatic potentials. In cell aggregation assays, PP2 stimulated the aggregation of colon, liver, and breast cancer cells. In vitro cultures of cancer cells showed that PP2 induced strong cell-cell contact. Immunoblot analysis showed that PP2 enhanced E-cadherin/catenin expression and that increased E-cadherin/catenin proteins were strongly associated with the actin cytoskeleton. Northern blot studies indicated that the observed increase of E-cadherin/catenin protein content was due to their increased gene expression. After the spleens of severe combined immunodeficient mice were inoculated with cancer cells, treatment with PP2 for 3 weeks markedly reduced the rate of liver metastasis, compared with the control counterparts. Our data demonstrate that PP2 can activate the functioning of the E-cadherin-mediated cell adhesion system, which is associated with the suppression of metastasis in cancer cells. Thus, selective inhibition of Src activation may be potentially useful in the prevention of cancer metastasis.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
L. J. Inge, S. A. Rajasekaran, D. Wolle, S. P. Barwe, S. Ryazantsev, C. M. Ewing, W. B. Isaacs, and A. K. Rajasekaran
{alpha}-Catenin overrides Src-dependent activation of {beta}-catenin oncogenic signaling
Mol. Cancer Ther., June 1, 2008; 7(6): 1386 - 1397.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J.-S. Nam, M. Terabe, M.-J. Kang, H. Chae, N. Voong, Y.-a. Yang, A. Laurence, A. Michalowska, M. Mamura, S. Lonning, et al.
Transforming Growth Factor {beta} Subverts the Immune System into Directly Promoting Tumor Growth through Interleukin-17
Cancer Res., May 15, 2008; 68(10): 3915 - 3923.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
A. Spreafico, S. Schenone, T. Serchi, M. Orlandini, A. Angelucci, D. Magrini, G. Bernardini, G. Collodel, A. Di Stefano, C. Tintori, et al.
Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells
FASEB J, May 1, 2008; 22(5): 1560 - 1571.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F.-P. Liang, C.-H. Lin, C.-D. Kuo, H.-P. Chao, and S.-L. Fu
Suppression of v-Src Transformation by Andrographolide via Degradation of the v-Src Protein and Attenuation of the Erk Signaling Pathway
J. Biol. Chem., February 22, 2008; 283(8): 5023 - 5033.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Fizazi
The role of Src in prostate cancer
Ann. Onc., November 1, 2007; 18(11): 1765 - 1773.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Dimri, M. Naramura, L. Duan, J. Chen, C. Ortega-Cava, G. Chen, R. Goswami, N. Fernandes, Q. Gao, G. P. Dimri, et al.
Modeling Breast Cancer-Associated c-Src and EGFR Overexpression in Human MECs: c-Src and EGFR Cooperatively Promote Aberrant Three-dimensional Acinar Structure and Invasive Behavior
Cancer Res., May 1, 2007; 67(9): 4164 - 4172.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Serrels, I. R.J. Macpherson, T.R. J. Evans, F. Y. Lee, E. A. Clark, O. J. Sansom, G. H. Ashton, M. C. Frame, and V. G. Brunton
Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib
Mol. Cancer Ther., December 1, 2006; 5(12): 3014 - 3022.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J.-S. Nam, M.-J. Kang, A. M. Suchar, T. Shimamura, E. A. Kohn, A. M. Michalowska, V. C. Jordan, S. Hirohashi, and L. M. Wakefield
Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells.
Cancer Res., July 15, 2006; 66(14): 7176 - 7184.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J.-S. Nam, A. M. Suchar, M.-J. Kang, C. H. Stuelten, B. Tang, A. M. Michalowska, L. W. Fisher, N. S. Fedarko, A. Jain, J. Pinkas, et al.
Bone Sialoprotein Mediates the Tumor Cell-Targeted Prometastatic Activity of Transforming Growth Factor {beta} in a Mouse Model of Breast Cancer.
Cancer Res., June 15, 2006; 66(12): 6327 - 6335.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H.-X. Yan, W. Yang, R. Zhang, L. Chen, L. Tang, B. Zhai, S.-Q. Liu, H.-F. Cao, X.-B. Man, H.-P. Wu, et al.
Protein-tyrosine Phosphatase PCP-2 Inhibits beta-Catenin Signaling and Increases E-cadherin-dependent Cell Adhesion
J. Biol. Chem., June 2, 2006; 281(22): 15423 - 15433.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. G. Trevino, J. M. Summy, D. P. Lesslie, N. U. Parikh, D. S. Hong, F. Y. Lee, N. J. Donato, J. L. Abbruzzese, C. H. Baker, and G. E. Gallick
Inhibition of Src Expression and Activity Inhibits Tumor Progression and Metastasis of Human Pancreatic Adenocarcinoma Cells in an Orthotopic Nude Mouse Model
Am. J. Pathol., March 1, 2006; 168(3): 962 - 972.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
C. E. Pullar and R. R. Isseroff
The {beta}2-adrenergic receptor activates pro-migratory and pro-proliferative pathways in dermal fibroblasts via divergent mechanisms
J. Cell Sci., February 1, 2006; 119(3): 592 - 602.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. M. Golas, J. Lucas, C. Etienne, J. Golas, C. Discafani, L. Sridharan, E. Boghaert, K. Arndt, F. Ye, D. H. Boschelli, et al.
SKI-606, a Src/Abl Inhibitor with In vivo Activity in Colon Tumor Xenograft Models
Cancer Res., June 15, 2005; 65(12): 5358 - 5364.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. G. Brunton, E. Avizienyte, V. J. Fincham, B. Serrels, C. A. Metcalf III, T. K. Sawyer, and M. C. Frame
Identification of Src-Specific Phosphorylation Site on Focal Adhesion Kinase: Dissection of the Role of Src SH2 and Catalytic Functions and Their Consequences for Tumor Cell Behavior
Cancer Res., February 15, 2005; 65(4): 1335 - 1342.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
F. Palacios, J. S. Tushir, Y. Fujita, and C. D'Souza-Schorey
Lysosomal Targeting of E-Cadherin: a Unique Mechanism for the Down-Regulation of Cell-Cell Adhesion during Epithelial to Mesenchymal Transitions
Mol. Cell. Biol., January 1, 2005; 25(1): 389 - 402.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
M. F. McCarty
Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380.
[Abstract] [PDF]

Home page
 J. Cell Biol.Home page
S. Weis, J. Cui, L. Barnes, and D. Cheresh
Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis
J. Cell Biol., October 25, 2004; 167(2): 223 - 229.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. Duxbury, H. Ito, M. J. Zinner, S. W. Ashley, and E. E. Whang
Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells
Clin. Cancer Res., April 1, 2004; 10(7): 2307 - 2318.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. M. Weinreich, D. M. Elaraj, M. Puhlmann, S. M. Hewitt, N. M. Carroll, E. D. Feldman, E. M. Turner, P. J. Spiess, and H. R. Alexander
Effect of Interleukin 1 Receptor Antagonist Gene Transduction on Human Melanoma Xenografts in Nude Mice
Cancer Res., September 15, 2003; 63(18): 5957 - 5961.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.